NTRP - Neurotrope, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
5.95
+0.44 (+7.99%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.51
Open5.55
Bid4.95 x 800
Ask5.94 x 900
Day's Range5.55 - 6.30
52 Week Range3.33 - 10.50
Volume96,982
Avg. Volume67,000
Market Cap77.037M
Beta (3Y Monthly)2.36
PE Ratio (TTM)N/A
EPS (TTM)-1.48
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • Biotech company offering Alzheimer’s disease patients hope with new drug
    Yahoo Finance Video7 months ago

    Biotech company offering Alzheimer’s disease patients hope with new drug

    Alzheimer’s disease affects some 5.7 million Americans, but biotech company Neurotrope is offering patients new hope with a drug it says shows a “reversal” in the disease. Yahoo Finance’s Alexis Christoforous speaks to Neurotrope CEO Dr. Charles Ryan about his company’s findings.

  • PR Newswire4 days ago

    Neurotrope Strategic Advisory Board Members Participating in Key Opinion Leader Call Sponsored by Oppenheimer's Biotechnology Team

    NEW YORK, July 17, 2019 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that two of the Company's Scientific Advisory Board members will be participating in a key opinion leader (KOL) call being sponsored by Oppenheimer & Co. Inc.'s Biotechnology team. Neurotrope's Chief Scientific Advisory Board members, Dr. Martin R. Farlow and Dr. Marwan Sabbagh, will be hosting the KOL / Oppenheimer call. Neurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases.

  • PR Newswire6 days ago

    Neurotrope Concludes Data Collection in Confirmatory Phase 2 Clinical Trial of Moderately Severe to Severe Alzheimer's Disease

    Data from the previous exploratory Phase 2 trial demonstrated clear safety and showed greater than baseline improvements in Severe Impairment Battery (SIB) scores that were sustained for patients in the 20µg Bryostatin-1 dose group not on memantine. The current confirmatory Phase 2, multi-center trial is designed to assess the safety and efficacy of Bryostatin-1 as a treatment for cognitive deficits in 108 patients with moderate to severe AD, defined as a Mini Mental State Exam 2 score of 4 - 15, who are not currently taking memantine.

  • PR Newswire10 days ago

    Neurotrope to Present at the Alzheimer's Association International Conference; Neurotrope President and Chief Scientific Officer, Dr. Daniel L. Alkon, to Receive Cure Coin Award; Design of Confirmatory Phase 2 Trial to be Presented

    NEW YORK, July 11, 2019 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical- stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer's disease ("AD") is announcing that Dr. Daniel L. Alkon, the Company's President and CSO, will be honored among the recipients of the Cure Coin Award, at the InvestAcure Cure Coin Awards Reception on July 15, 2019 during the Alzheimer's Association International Conference in Los Angeles. "We are proud to honor Dr. Alkon for his work in the development of Bryostatin, a natural compound showing promise in restoring synaptic networks in the brain, preventing neuronal death, clearing Tau and Amyloid buildup, and reversing Alzheimer's memory loss even for patients with late-stage disease," said Max Tokarsky, Founder & CEO of InvestAcure, PBC.

  • PR Newswire27 days ago

    Neurotrope CEO to Present at the Maxim Group Key Opinion Leader Discussion on Alzheimer's Disease on June 26th, 2019

    NEW YORK, June 24, 2019 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announced that Dr. Charles S. Ryan, CEO, will be a featured presenter at the Maxim Group Key Opinion Leader Discussion "Alzheimer's disease – What's Next? Dr. Ryan will provide an overview of the Company's business model and growth strategy and will be available for one-on-one meetings. Neurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases.

  • PR Newswire2 months ago

    Neurotrope's President and Chief Scientific Officer to Present at the Alzheimer's Solutions Conference at The University of the Sciences in Philadelphia, PA on June 3rd, 2019

    NEW YORK, June 3, 2019 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), announced that Dr. Daniel L. Alkon, the Company's President and CSO, will speak in Session II. From News Headlines to Patients: Clinical Trial Ready Drugs (Part I). Dr. Alkon's presentation - Bryostatin: A Natural Compound from the Depths of the Ocean to Help Restore Neural Pathways and Reverse Alzheimer's Memory Loss, will take place at the University of the Sciences at 600 S. 43rd St., Philadelphia, PA on Monday, June 3rd, 2019, from 11:30am to 11:45am eastern time (Link- www.investacure.com).

  • PR Newswire2 months ago

    Neurotrope to Present at the LD Micro 9th Annual Invitational Conference on June 4, 2019

    Dr. Ryan will provide an overview of the Company's business model and growth strategy and will be available for one-on-one meetings. For those interested in attending, or for registered attendees who wish to request meetings, please contact David Scher, via email, at david@ldmicro.com or visit www.ldmicro.com for more information. Neurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases.

  • Investors Who Bought Neurotrope (NASDAQ:NTRP) Shares Five Years Ago Are Now Down 87%
    Simply Wall St.2 months ago

    Investors Who Bought Neurotrope (NASDAQ:NTRP) Shares Five Years Ago Are Now Down 87%

    It is doubtless a positive to see that the Neurotrope, Inc. (NASDAQ:NTRP) share price has gained some 38% in the last...

  • PR Newswire3 months ago

    Neurotrope Announces Inducement Grant to Newly-Appointed Chief Operating Officer and General Counsel

    NEW YORK, April 19, 2019 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, including Alzheimer's disease ("AD"), today announced the authorization of an inducement grant to newly-appointed Chief Operating Officer and General Counsel, Michael Ciraolo, J.D., Ph.D. As previously announced, Dr. Ciraolo comes to Neurotrope from Ovid Therapeutics, where he served as senior vice president, chief intellectual property counsel.  Prior to joining Ovid, he was an executive director at Forest Laboratories, where he held positions of increasing levels of responsibility.   He has been involved with the development of numerous pharmaceutical products and transactional matters, including mergers, acquisitions and licensing opportunities.

  • PR Newswire4 months ago

    Neurotrope Appoints Dr. Michael Ciraolo As General Counsel And Chief Operating Officer

    NEW YORK, April 1, 2019 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease ("AD"), announced today that Michael Ciraolo, J.D., Ph.D., is joining the Company as general counsel and chief operating officer. "I am very pleased to welcome Michael to the Neurotrope executive management team," said Charles Ryan, Neurotrope's chief executive officer. "He is an exceptional leader and lawyer and we expect will prove instrumental as we continue to execute at this important point in the Company's evolution.

  • PR Newswire4 months ago

    Neurotrope Comments On Biogen's Discontinued Phase 3 Trial In Alzheimer's Disease

    NEW YORK, March 21, 2019 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today issued a statement on Biogen Inc.'s decision to discontinue its global Phase 3 trials of aducanunab in Alzheimer's disease. Neurotrope CEO, Dr. Charles Ryan, said in a statement, "We are deeply saddened to hear the news that Biogen and Eisai's efforts have fallen short. The promising data from our previous exploratory Phase 2 trial showed greater than baseline improvements in Severe Impairment Battery (SIB) scores for patients in the 20 µg Bryostatin-1 dose group, suggesting the potential to translate Bryostatin's neurorestorative properties in the clinic.

  • PR Newswire4 months ago

    Neurotrope Completes Enrollment Of Confirmatory Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease

    NEW YORK, March 13, 2019 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that it has initiated dosing in the final patient in the Company's randomized, double-blind, placebo-controlled, confirmatory Phase 2 clinical trial of Bryostatin-1 in moderate to severe AD patients not on memantine. "Completion of enrollment in our confirmatory Phase 2 trial is an important step toward understanding the transformative potential of Bryostatin in moderate to severe Alzheimer's disease, a neglected area of AD research with no effective treatment options," stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope.

  • PR Newswire4 months ago

    Neurotrope Reports Year End 2018 Financial Results

    NEW YORK, March 11, 2019 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease ("AD"), provided financial results for the year ended December 31, 2018. As of December 31, 2018, the Company had approximately $28.8 million of cash and cash equivalents. The Company raised approximately $20.5 million of net cash proceeds in December 2018.  With these funds and its cash on hand, the Company estimates that it has between 24 and 36 months of cash for continuing operations.

  • PR Newswire5 months ago

    Neurotrope to Participate in the BIO CEO & Investor Conference

    NEW YORK, Feb. 8, 2019 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Charles Ryan, J.D., Ph.D., Neurotrope's Chief Executive Officer, will be participating in an educational panel entitled, "Attacking Biological Mechanisms of Aging to Extend Healthspan" at the BIO CEO & Investor Conference in New York on Monday, February 11th, 2019 at 3:30 p.m. Eastern Time. Neurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases. The Company's world-class science offers the potential to realize a paradigm shift to overcome one of today's most challenging clinical problems — finding a way to slow or even prevent the progression of AD.

  • PR Newswire5 months ago

    Neurotrope Announces Cooperative Research and Development Agreement for Bryostatin-1 with the National Cancer Institute

    NEW YORK, Feb. 4, 2019 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the research and clinical development of Bryostatin-1.

  • PR Newswire7 months ago

    Neurotrope to Participate in the Sachs Associates 2nd Annual Neuroscience Innovation Forum

    NEW YORK, Jan. 3, 2019 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that Daniel Alkon, M.D., Neurotrope's President and Chief Scientific Officer, will be participating in a panel discussion entitled "Progress in Alzheimer's" at the Sachs Associates 2nd Annual Neuroscience Innovation Forum in San Francisco on Sunday, January 6th, 2019 at 10:25 a.m. Pacific Time. Neurotrope is at the forefront of developing a new approach to combating AD and other neurodegenerative diseases. The Company's world-class science offers the potential to realize a paradigm shift to overcome one of today's most challenging clinical problems — finding a way to slow or even prevent the progression of AD.

  • PR Newswire7 months ago

    Neurotrope Announces the Appointment of Two New Board Members

    Dr. Ivan Gergel Brings Clinical Expertise and Product Development Leadership Resulting in Industry-Leading Product Launches Including Namenda® for Alzheimer's Disease Jonathan Schechter Brings Deep Financial ...

  • PR Newswire7 months ago

    Neurotrope Announces Publication of Phase 2 Study of Bryostatin-1 in Moderate to Severe Alzheimer's Disease in the Journal of Alzheimer's Disease

    NEW YORK, Dec. 17, 2018 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease (AD), today announced that data from its Phase 2, multidose, exploratory trial evaluating Bryostatin-1 as a treatment of cognitive deficits in moderate to severe Alzheimer's disease were published online in the Journal of Alzheimer's Disease. The double-blind, placebo-controlled, Phase 2 trial, which was completed in May 2017, randomized patients 1:1:1 into 20 μg Bryostatin-1, 40 μg Bryostatin-1, and placebo arms.

  • PR Newswire7 months ago

    Neurotrope Announces $22.5 Million Registered Direct Offering

    NEW YORK, Dec. 17, 2018 /PRNewswire/ -- Neurotrope, Inc. (NTRP) today announced the pricing of a registered direct offering of 5,012,677 shares of common stock and warrants to purchase up to an aggregate of 5,012,677 shares of common stock to institutional and other accredited investors.  Each share of common stock is being sold together with a warrant to purchase one share of common stock for a combined purchase price of $4.495, resulting in gross proceeds of approximately $22.5 million. The shares of common stock and the warrants will be immediately separable and will be issued separately. A final prospectus supplement related to the offering will be filed with the SEC, and will be available on the SEC's website located at http://www.sec.gov and may also be obtained from GP Nurmenkari Inc., 22 Elizabeth Street Sono Square, Suite 1J, Norwalk, CT 06854 or by calling (212) 447-5550.

  • GlobeNewswire8 months ago

    Report: Developing Opportunities within Command Center, Neurotrope, Selecta Biosciences, InVivo Therapeutics, SeaSpine, and Senestech — Future Expectations, Projections Moving into 2018

    NEW YORK, Nov. 19, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Neurotrope Presents Updated Phase 2 Data of Bryostatin-1 in Moderate to Severe Alzheimer's Disease at the 11th Edition of CTAD
    PR Newswire9 months ago

    Neurotrope Presents Updated Phase 2 Data of Bryostatin-1 in Moderate to Severe Alzheimer's Disease at the 11th Edition of CTAD

    NEW YORK, Oct. 24, 2018 /PRNewswire/ -- Neurotrope Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced the presentation of updated data from the Phase 2, multidose, exploratory trial evaluating Bryostatin-1 as a treatment of cognitive deficits in moderate to severe Alzheimer's disease ("AD"). The data were presented in a poster, entitled "Evidence of Sustained Low Dose Bryostatin Efficacy for Treatment of Alzheimer's Disease: Consistency of Multiple Evaluation Analyses" at the 11th Edition of Clinical Trials on Alzheimer's Disease ("CTAD") being held in Barcelona, Spain from October 24th - 27th, 2018. "We are encouraged by the findings of this exploratory trial as we believe they are suggestive of the primary mechanisms of action of bryostatin, synaptogenesis and anti-apoptosis, or the generation of new, mature synaptic connections and the prevention of neuronal death," stated Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope.

  • PR Newswire10 months ago

    Neurotrope to Present at the Ladenburg Thalmann 2018 Healthcare Conference

    NEW YORK, Sept. 27, 2018 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced that Dr. Charles Ryan, Neurotrope's Chief Executive Officer, will present a company overview at the Ladenburg Thalmann 2018 Healthcare Conference in New York on Tuesday, October 2nd, 2018 at 9:30 a.m. Eastern Time. A live webcast of the presentation will be available on the "Events and Presentations" page in the "Investors and Media" section of the Company's website at http://www.neurotrope.com/. The presentation will be archived on the Company's website and be available for replay for 90 days.

  • PR Newswire10 months ago

    Neurotrope to Present Additional Phase 2 Data at the 11th Edition of Clinical Trials on Alzheimer's Disease (CTAD2018)

    NEW YORK, Sept. 26, 2018 /PRNewswire/ -- Neurotrope, Inc. (NTRP), a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases, including Alzheimer's disease, today announced that updated data on its lead compound, bryostatin, will be presented during the 11th Edition of Clinical Trials on Alzheimer's Disease to be held in Barcelona, Spain from October 24th - 27th, 2018. "Leveraging decades of work on the PKC pathway at NIH and other leading institutions, bryostatin uses a novel mechanism of action to generate new, mature synaptic connections and prevent neuronal death in Alzheimer's disease models," said Dr. Daniel Alkon, President and Chief Scientific Officer of Neurotrope. "We are highly encouraged by the translation of this work to the clinic, with results from our Phase 2 study in Alzheimer's disease showing promising early signals of clinical improvement in moderate to severe AD patients, a population largely neglected in drug development.

  • PR Newswire10 months ago

    Neurotrope Enters into Collaboration with the Nemours / Alfred I. duPont Hospital for Children to Initiate a Clinical Trial in Fragile X Syndrome

    NEW YORK, Sept. 5, 2018 /PRNewswire/ -- Neurotrope Inc. (NTRP) a clinical-stage biopharmaceutical company developing novel therapies for neurodegenerative and neurodevelopmental disorders, including Alzheimer's disease (AD), is announcing a collaboration with The Nemours / Alfred I. duPont Hospital for Children ("Nemours") to initiate a clinical trial in children with Fragile X Syndrome ("Fragile X").  The planned protocol for the pilot open-label trial will dose Fragile X patients from 8 to less than 18 years of age, using a dosing regimen similar to that being tested in AD patients. In addition to the primary objective of safety and tolerability, measurements will be made of working memory, language and other functional aspects such as anxiety, repetitive behavior, executive functioning, and social behavior.   "We are delighted to be collaborating with clinical scientists at Nemours on this important study for Fragile X.  As one of the premier children's hospitals in the United States, this hospital has both the patient population and the clinical team required to execute this study," stated Dr. Charles Ryan, Chief Executive Officer of Neurotrope.

  • Neurotrope Sees Hammer Chart Pattern: Time to Buy?
    Zacks11 months ago

    Neurotrope Sees Hammer Chart Pattern: Time to Buy?

    Neurotrope, Inc. (NTRP) has been struggling lately, but the selling pressure may be coming to an end soon.